Subchapter V Reorganization of a Clinical Diagnostics Laboratory
Facility. Bridge Diagnostics operated as a clinical medical laboratory in Irvine/Aliso Viejo, California. A facility design profile from LPA Design Studios describes a purpose-built diagnostics facility totaling 24,000 square feet lpadesignstudios.com: Bridge Diagnostics Facility Design (LPA Design Studios, 2021) (outside source), including 14,000 square feet of lab space and 10,000 square feet of office space, built as an expansion from a prior 6,500 square foot facility.
An NPI profile lists Bridge Diagnostics LLC as a "Clinical Medical Laboratory" with an NPI assigned in May 2020 npiprofile.com: Bridge Diagnostics NPI Profile (NPI Profile, 2020) (outside source) and identifies Jason Hansen as the authorized official. A CLIA listing describes an independent lab certificate of accreditation for nonwaived testing labprospects.com: Bridge Diagnostics CLIA Certification (LabProspects, 2024) (outside source) under CLIA number 05D2184382.
| Item | Publicly described details |
|---|
| Facility size | 24,000 sq. ft. total; 14,000 lab; 10,000 office |
| NPI | 1881215622 (Clinical Medical Laboratory) |
| CLIA | 05D2184382 (Certificate of Accreditation; nonwaived testing) |
Table: Operations snapshot (public records)
One growth database estimated revenue of $10.8 million and 50 employees growjo.com: Bridge Diagnostics Revenue and Employee Data (Growjo, 2024) (outside source) (down from 97 the prior year). Other directories list wider ranges (e.g., 51–200 or 100–200 employees linkedin.com: Bridge Diagnostics LinkedIn Company Profile (LinkedIn, 2024) (outside source)) and describe the company as operating in hospitals and healthcare or diagnostic testing signalhire.com: Bridge Diagnostics Company Overview (SignalHire, 2024) (outside source).
A BBB profile for Bridge Diagnostics lists a company start date of April 1, 2020, a location in Irvine, and a B- rating bbb.org: Bridge Diagnostics LLC Business Profile (Better Business Bureau, 2023-11-06) (outside source), stating that the company was not accredited and that one complaint had been filed without a response.
Distress drivers. Bankruptcy filings describe the company as scaling rapidly during COVID testing and then pivoting back toward pre-pandemic testing lines. The filings describe a revenue decline tied to coverage changes affecting a PCR-based UTI testing product line and unpaid COVID-related receivables. The filings also describe workforce reductions and a strategic shift toward pharmacogenomic testing.
The LinkedIn profile describes a focus on pharmacogenomics and "precision medicine data," linkedin.com: Bridge Diagnostics LinkedIn Company Profile (LinkedIn, 2024) (outside source) framing the company's aim as bridging diagnostics and therapeutics. A company directory similarly describes infectious diseases and women's health signalhire.com: Bridge Diagnostics Company Overview (SignalHire, 2024) (outside source) alongside pharmacogenomics.
Cash collateral. Early in the case, the debtor filed a Cash Collateral Motion Dkt. 22. Bridge subsequently sought additional postpetition financing rather than relying solely on cash collateral arrangements.
Postpetition financing. The Postpetition Loan Motion Dkt. 52 describes a loan facility of up to $800,000, with interim approval for $100,000, priced at 5% interest per annum compounded annually, and maturing on December 31, 2026. The filings describe the loan as being secured by a priming first-priority lien on substantially all assets (excluding avoidance actions).
| Term | Reported financing terms |
|---|
| Maximum borrowing | $800,000 total (interim approval for $100,000) |
| Interest | 5% per annum, compounded annually |
| Maturity | December 31, 2026 |
| Collateral |
Table: Postpetition loan terms (high level)
Plan structure. Bridge filed multiple iterations of a chapter 11 plan and ultimately proceeded on a Second Amended Plan confirmed in September 2024. The plan included a granular secured creditor matrix (Class 1(a) through 1(m)), a dedicated insurer-related class (Class 2 for Blue Cross of California and Anthem Blue Cross Life), and a general unsecured class (Class 3). A portion of a secured claim held by "Hansen" was recharacterized into general unsecured treatment, and certain equipment collateral was surrendered to BayCap, with any deficiency treated as general unsecured claims.
| Class (high level) | Constituency | Treatment concepts described |
|---|
| Class 1(a)–1(m) | Secured creditors | Individualized treatment by creditor/collateral package |
| Class 2 | Blue Cross of California; Anthem Blue Cross Life | Insurer-related claims grouped into a dedicated class |
|
Table: Plan class structure (high level)
Key professionals. A bankruptcy database listing identifies debtor counsel as Marshack Hays Wood LLP bkdata.com: Bridge Diagnostic, LLC Files for Bankruptcy (BKData, 2024-03-29) (outside source) (David Wood, counsel of record). Public profiles identify Jason Hansen as founder and CEO, with prior experience founding Precision Diagnostics theorg.com: Jason Hansen - Founder/CEO (The Org, 2024) (outside source) (founded in 2011) before founding Bridge Diagnostics in April 2020.
| Role | Publicly identified name / firm |
|---|
| Debtor counsel | Marshack Hays Wood LLP (David Wood) |
| CEO / founder | Jason Hansen |
Table: Key people (public sources)
Timeline. Bridge filed in late March 2024, moved through early liquidity motions in April, filed an initial plan in late June, amended the plan in August, and reached confirmation in September.
| Date | Case milestone (high level) |
|---|
| March 29, 2024 | chapter 11 Subchapter V petition filed |
| April 2024 | cash collateral motion filed |
| April 2024 | postpetition loan motion filed |
| June 24, 2024 |
Table: Case timeline (selected)